Literature DB >> 16985842

Drug-induced urinary calculi.

Brian R Matlaga, Ojas D Shah, Dean G Assimos.   

Abstract

Urinary calculi may be induced by a number of medications used to treat a variety of conditions. These medications may lead to metabolic abnormalities that facilitate the formation of stones. Drugs that induce metabolic calculi include loop diuretics; carbonic anhydrase inhibitors; and laxatives, when abused. Correcting the metabolic abnormality may eliminate or dramatically attenuate stone activity. Urinary calculi can also be induced by medications when the drugs crystallize and become the primary component of the stones. In this case, urinary supersaturation of the agent may promote formation of the calculi. Drugs that induce calculi via this process include magnesium trisilicate; ciprofloxacin; sulfa medications; triamterene; indinavir; and ephedrine, alone or in combination with guaifenesin. When this situation occurs, discontinuation of the medication is usually necessary.

Entities:  

Year:  2003        PMID: 16985842      PMCID: PMC1508366     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  23 in total

1.  Ephedrine nephrolithiasis associated with chronic ephedrine abuse.

Authors:  J J Blau
Journal:  J Urol       Date:  1998-09       Impact factor: 7.450

2.  Sulfonamide crystalluria: a forgotten disease.

Authors:  L E Dorfman; J P Smith
Journal:  J Urol       Date:  1970-09       Impact factor: 7.450

3.  Silicate urolithiasis.

Authors:  J H Farrer; J Rajfer
Journal:  J Urol       Date:  1984-10       Impact factor: 7.450

4.  Unusual complication of therapy with sulfamethoxazole-trimethoprim.

Authors:  W H Siegel
Journal:  J Urol       Date:  1977-03       Impact factor: 7.450

Review 5.  Topiramate: a review of preclinical, pharmacokinetic, and clinical data.

Authors:  W E Rosenfeld
Journal:  Clin Ther       Date:  1997 Nov-Dec       Impact factor: 3.393

Review 6.  Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy.

Authors:  D H Peters; E M Sorkin
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

7.  Renal calcifications: a complication of long-term furosemide therapy in preterm infants.

Authors:  K G Hufnagle; S N Khan; D Penn; A Cacciarelli; P Williams
Journal:  Pediatrics       Date:  1982-09       Impact factor: 7.124

8.  Urine composition and stone formation during treatment with acetazolamide.

Authors:  C Ahlstrand; H G Tiselius
Journal:  Scand J Urol Nephrol       Date:  1987

9.  Pharmacology of furosemide in the premature newborn infant.

Authors:  R G Peterson; M A Simmons; B H Rumack; R L Levine; J G Brooks
Journal:  J Pediatr       Date:  1980-07       Impact factor: 4.406

10.  Acetazolamide-induced nephrocalcinosis.

Authors:  J R Parikh; R L Nolan
Journal:  Abdom Imaging       Date:  1994 Sep-Oct
View more
  16 in total

1.  Alkali replacement raises urinary citrate excretion in patients with topiramate-induced hypocitraturia.

Authors:  R Allan Jhagroo; Margaret L Wertheim; Kristina L Penniston
Journal:  Br J Clin Pharmacol       Date:  2015-12-10       Impact factor: 4.335

2.  Guaifenesin stone matrix proteomics: a protocol for identifying proteins critical to stone formation.

Authors:  A M Kolbach-Mandel; N S Mandel; S R Cohen; J G Kleinman; F Ahmed; I C Mandel; J A Wesson
Journal:  Urolithiasis       Date:  2016-07-19       Impact factor: 3.436

3.  Ceftriaxone associated nephrolithiasis: a prospective study in 284 children.

Authors:  Masoumeh Mohkam; Abdollah Karimi; Atoosa Gharib; Hamid Daneshmand; Alireza Khatami; Nozar Ghojevand; Mostafa Sharifian
Journal:  Pediatr Nephrol       Date:  2007-01-17       Impact factor: 3.714

Review 4.  Pediatric urolithiasis: causative factors, diagnosis and medical management.

Authors:  Funda Baştuğ; Ruhan Düşünsel
Journal:  Nat Rev Urol       Date:  2012-02-07       Impact factor: 14.432

Review 5.  Histological aspects of the "fixed-particle" model of stone formation: animal studies.

Authors:  Saeed R Khan
Journal:  Urolithiasis       Date:  2016-11-28       Impact factor: 3.436

6.  Increasing urinary calcium excretion after ceftriaxone and cephalothin therapy in adults: possible association with urolithiasis.

Authors:  Alper Otunctemur; Emin Ozbek; Emre Can Polat; Mustafa Cekmen; Murat Dursun; Suleyman Sami Cakir
Journal:  Urolithiasis       Date:  2013-12-06       Impact factor: 3.436

Review 7.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

8.  How do stones form? Is unification of theories on stone formation possible?

Authors:  Victoria Y Bird; Saeed R Khan
Journal:  Arch Esp Urol       Date:  2017-01       Impact factor: 0.436

9.  Imaging MS in Toxicology: An Investigation of Juvenile Rat Nephrotoxicity Associated with Dabrafenib Administration.

Authors:  M Reid Groseclose; Susan B Laffan; Kendall S Frazier; Angela Hughes-Earle; Stephen Castellino
Journal:  J Am Soc Mass Spectrom       Date:  2015-03-25       Impact factor: 3.109

10.  Nephrolithiasis caused by ceftriaxone in a 3-year-old child with ureteropelvic junction obstruction.

Authors:  Vesna Stojanovic; Gordana Djuric Vijatov
Journal:  Case Rep Med       Date:  2009-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.